54232-04-1

Basic information

• Product Name: 3-Pyridinol, 6-chloro-5-methyl-, acetate (ester)
• Synonyms: 3-Pyridinol, 6-chloro-5-methyl-, acetate (ester);6-chloro-5-methylpyridin-3-yl acetate
• CAS NO: 54232-04-1
• Molecular Formula: C8H8ClNO2
• Molecular Weight: 185.61
• Mol File: 54232-04-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Pyridinol, 6-chloro-5-methyl-, acetate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinol, 6-chloro-5-methyl-, acetate (ester)(54232-04-1)
• EPA Substance Registry System: 3-Pyridinol, 6-chloro-5-methyl-, acetate (ester)(54232-04-1)

Safety Data

• Hazardous Substances Data: 54232-04-1(Hazardous Substances Data)

Upstream product

• 109-63-7 trifluoroborane diethyl ether 
• 38186-82-2 6-chloro-5-methylpyridin-3-amine 
• 22280-56-4 2-chloro-3-methyl-5-nitropyridine 
• 108-24-7 acetic anhydride 

Downstream Products

• 54232-03-0 2-chloro-5-hydroxy-3-methylpyridine 
• 1624607-03-9 2-chloro-5-((4-methoxybenzyl)oxy)-3-methylpyridine 
• 1624607-04-0 5-((4-methoxybenzyl)oxy)-3-methyl-2-vinylpyridine 
• 228867-86-5 5-hydroxy-3-methylpyridine-2-carbonitrile 

Relevant articles and documents

CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

3-Pyridyl enantiomers and their use as analgesics

The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: STR1 or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.